These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke. Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770 [TBL] [Abstract][Full Text] [Related]
4. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
5. The iScore predicts clinical response to tissue plasminogen activator in Korean stroke patients. Park TH; Park SS; Ko Y; Lee SJ; Lee KB; Lee J; Kang K; Park JM; Choi JC; Kim DE; Cho YJ; Hong KS; Kim JT; Kim DH; Cha JK; Han MK; Lee JS; Lee J; Yu KH; Lee BC; Yoon BW; Bae HJ; Saposnik G J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):367-73. PubMed ID: 23800501 [TBL] [Abstract][Full Text] [Related]
6. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734 [TBL] [Abstract][Full Text] [Related]
7. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398 [TBL] [Abstract][Full Text] [Related]
8. Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World. Suzuki J; Nakai N; Kondo N; Tsuji H; Inagaki R; Furukawa S; Iwata M; Nishida S; Ito Y Cerebrovasc Dis; 2018; 46(3-4):184-192. PubMed ID: 30384371 [TBL] [Abstract][Full Text] [Related]
9. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513 [TBL] [Abstract][Full Text] [Related]
11. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429 [TBL] [Abstract][Full Text] [Related]
12. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579 [TBL] [Abstract][Full Text] [Related]
13. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis. Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038 [TBL] [Abstract][Full Text] [Related]
14. A model to prevent fibrinolysis in patients with stroke mimics. Chang J; Teleb M; Yang JP; Alderazi YJ; Chapple K; Frey JL; Restrepo L J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):839-43. PubMed ID: 21640609 [TBL] [Abstract][Full Text] [Related]
15. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. Saver JL; Fonarow GC; Smith EE; Reeves MJ; Grau-Sepulveda MV; Pan W; Olson DM; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2013 Jun; 309(23):2480-8. PubMed ID: 23780461 [TBL] [Abstract][Full Text] [Related]
16. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke. Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601 [TBL] [Abstract][Full Text] [Related]
17. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916 [TBL] [Abstract][Full Text] [Related]
19. Stroke Mimics: An Important Source of Bias in Acute Ischemic Stroke Research. Garg R; Rech MA; Schneck M J Stroke Cerebrovasc Dis; 2019 Sep; 28(9):2475-2480. PubMed ID: 31256984 [TBL] [Abstract][Full Text] [Related]
20. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012. Tong X; George MG; Yang Q; Gillespie C Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]